EMAT
Combination Post-transplant Consolidation Therapy With Isatuximab, Lenalidomide, Dexamethasone (IsaRD) in Multiple Myeloma Patients With Persistent Marrow Minimal Residual Disease (Elimination of MRD After Transplant; E-MAT)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 31 patients (estimated)
- Sponsors
- Medical College of Wisconsin
- Tags
- Monoclonal Antibody, CD38, Minimal Residual Disease (MRD)
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1902
- NCT Identifier
- NCT05690984
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.